ContraVir Pharmaceuticals (NASDAQ:CTRV) provided new insights into the mechanism of action of its hepatitis B (HBV) cyclophilin inhibitor, CRV431, showing that it effectively blocks a critical interaction between HBV X protein (HBx) and host cyclophilin A, with nanomolar potency.Read More
William Blair initiated coverage at “outperform” of four biotech companies that are strategically positioned to benefit from the hepatitis B virus frontier.
“Curing chronic hepatitis B infections is the next frontier after solving the hepatitis C problem, and the markets for both disease cures could be similar in size, reaching $200-billion each in cumulative global sales over a span of two decades,” writes analyst Katherine Xu.Read More
Roth Capital Partners has initiated coverage of PhaseRx (NASDAQ:PZRX) with a “buy” rating and 12-month price target of $8. The stock closed at $5 on Thursday.
“In our opinion, PhaseRx’s technology platform, combined with promising preclinical results, first mover advantage in the multi-billion dollar i-ERT market opportunity, a number of potential upcoming milestones, and a unique scarcity value, make PhaseRx shares well positioned to perform in the coming 12-to-18 months,” writes analyst Sa’ar Yaniv.Read More